Investing.com - Jounce Therapeutics reported on Thursday third quarter earnings that beat analysts' forecasts and revenue that fell short of expectations.
Jounce Therapeutics announced earnings per share of $-0.600 on revenue of $0.00. Analysts polled by Investing.com anticipated EPS of $-0.620 on revenue of $2.5M.
Jounce Therapeutics shares are down 4.96% from the beginning of the year and are trading at $1.710 , down-from-52-week-high.
Jounce Therapeutics shares lost 14.07% in intra-day trade following the report.
Jounce Therapeutics follows other major Healthcare sector earnings this month
Jounce Therapeutics's report follows an earnings beat by UnitedHealth on Friday, October 14, 2022, who reported EPS of $5.79 on revenue of $80.89B, compared to forecasts EPS of $5.43 on revenue of $80.52B.
J&J had beat expectations on Tuesday, October 18, 2022 with third quarter EPS of $2.55 on revenue of $23.79B, compared to forecast for EPS of $2.52 on revenue of $23.46B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar